Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.
The mammalian heart expresses at least five phosphodiesterases (PDE1-5). Catecholamines produce surges of inotropically relevant cAMP through beta(1)-adrenoceptor stimulation. cAMP is mainly hydrolysed by PDE3 and/or PDE4 thereby blunting contractility. Basal sinoatrial beating rate in mouse, rat, piglet and rabbit sinoatrial cells is reduced by PDE3 and/or PDE4 through hydrolysis of cAMP. However, in rodents, the tachycardia elicited by catecholamines through production of cAMP by beta-adrenoceptor activation is not controlled by PDE3 and PDE4, despite a blunting effect of PDE3 or/and PDE4 on basal sinoatrial beating, but it is unknown whether PDE3 limits catecholamine-evoked tachycardia in the rabbit. Since rabbit sinoatrial cells are an important model for pacemaker research, we investigated whether the positive chronotropic effects of (-)-noradrenaline on spontaneously beating right atria of the rabbit are potentiated by inhibition of PDE3 with cilostamide (300 nM). We also studied the sinoatrial effects of the PDE4 inhibitor rolipram (10 microM) and its influence on the responses to (-)-noradrenaline. For comparison, we investigated the influence of cilostamide and rolipram on the positive inotropic responses to (-)-noradrenaline on rabbit left atria and right ventricular papillary muscles. Cilostamide and concurrent cilostamide + rolipram, but not rolipram alone, increased sinoatrial rate by 15% and 31% of the effect of (-)-isoprenaline (200 microM) but the PDE inhibitors did not significantly change the chronotropic potency of (-)-noradrenaline. In contrast in papillary muscle, the positive inotropic effects of (-)-noradrenaline were potentiated 2.4-, 2.6- and 44-fold by cilostamide, rolipram and concurrent cilostamide + rolipram, respectively. In left atrium, the positive inotropic effects of (-)-noradrenaline were marginally potentiated by cilostamide, as well as potentiated 2.7- and 32-fold by rolipram and by concurrent cilostamide and rolipram respectively. To compare the influence of PDE1-5 on basal sinoatrial rate and (-)-noradrenaline-evoked tachycardia, we investigated on rat right atria the effects of selective inhibitors. The PDE4 inhibitor rolipram and non-selective inhibitor isobutyl-methylxanthine caused tachycardia with -logEC(50)s of 7.2 and 5.0 and E(max) of 18% and 102% of (-)-isoprenaline, respectively. Rolipram did not change the chronotropic potency of (-)-noradrenaline. At high concentrations (10-30 microM), the PDE1, PDE3 and PDE5 inhibitors 8-methoxymethyl-3-isobutyl-1-methylxanthine, cilostamide and sildenafil, respectively, caused marginal tachycardia but did not significantly change the chronotropic potency of (-)-noradrenaline. The PDE2-selective inhibitor erythro-9-[2-hydroxy-3-nonyl]adenine caused marginal bradycardia at 30 microM and tended to reduce the chronotropic potency of (-)-noradrenaline. Rabbit PDE3 reduces basal sinoatrial rate. Although PDE4 only marginally reduces rate, under conditions of PDE3 inhibition, it further reduces sinoatrial rate. Both PDE3 and PDE4 control atrial and ventricular positive inotropic effects of (-)-noradrenaline. In contrast, neither PDE3 nor PDE4 limit the sinoatrial tachycardia induced by (-)-noradrenaline. In the rat, only PDE4, but not PDE1, PDE2, PDE3 and PDE5, reduces basal sinoatrial rate. None of the five rat PDEs limits the (-)-noradrenaline-evoked tachycardia. Taken together, these results confirm and expand evidence for our proposal that the cAMP-compartment modulating basal sinoatrial rate, controlled by PDE3 and/or PDE4, is different from the PDE-resistant cAMP compartment involved in beta(1)-adrenoceptor-mediated sinoatrial tachycardia.
Kaumann
Alberto J
AJ
Department of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Physiology Building, Cambridge, CB2 3EG, UK. ajk41@hermes.cam.ac.uk
Galindo-Tovar
Alejandro
A
Escudero
Elisa
E
Vargas
María Luisa
ML
D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism*; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3 / Q000378:metabolism; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D018342:Receptors, Adrenergic, beta-1 / Q000378:metabolism*; D012849:Sinoatrial Node / Q000503:physiopathology; D013610:Tachycardia / Q000503:physiopathology*
D010726:Phosphodiesterase Inhibitors; D018342:Receptors, Adrenergic, beta-1; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4
J Mol Cell Cardiol. 2009 Aug;47(2):304-14
19345227
J Cardiovasc Pharmacol. 1992;20(5):715-22
1280732
Br J Pharmacol. 1991 Oct;104(2):471-7
1665737
Cell Signal. 1995 Sep;7(7):733-8
8519602
J Med Chem. 1999 Mar 25;42(6):1088-99
10090791
Circ Res. 2008 Apr 11;102(7):761-9
18276917
J Biol Chem. 1991 Jul 15;266(20):13385-90
1649189
Circulation. 2005 Oct 25;112(17):2642-9
16246964
Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):123-31
17318500
Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H594-615
19136600
J Androl. 2004 Jul-Aug;25(4):625-9
15223851
J Biol Chem. 1987 Jan 5;262(1):333-9
3025209
Br J Pharmacol. 2006 Jan;147(2):158-63
16331293
Circ Res. 2006 Mar 3;98(4):505-14
16424365
J Biol Chem. 1993 Dec 15;268(35):26286-95
7902837
Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):56-69
1685558
Br J Pharmacol. 1999 May;127(1):65-74
10369457
J Mol Cell Cardiol. 2009 Aug;47(2):157-70
19361514
Pharmacol Rev. 2006 Sep;58(3):488-520
16968949
Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):379-84
19005642
Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):60-70
2999616
Proc Biol Sci. 1996 Mar 22;263(1368):241-8
8920247
J Physiol. 1991 Nov;443:387-404
1668341
Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):249-53
17106669
Gene. 1998 Aug 17;216(1):139-47
9714779
Br J Pharmacol. 2002 Jun;136(3):421-33
12023945
Biochem Pharmacol. 2000 Feb 15;59(4):347-56
10644042
Br J Pharmacol. 2009 Jan;156(1):62-83
19133992
FEBS J. 2007 Sep;274(18):4812-24
17697115
Nature. 1991 May 9;351(6322):145-7
1709448
Br J Pharmacol. 2008 Feb;153(4):710-20
18084319
Br J Pharmacol. 2002 May;136(2):217-29
12010770
Circ Res. 2006 Oct 13;99(8):816-28
17038651
J Pharmacol Exp Ther. 1977 Jun;201(3):678-88
194027
Jpn J Pharmacol. 2002 Mar;88(3):362-4
11949894
Circ Res. 2001 Jun 22;88(12):1254-8
11420301
J Cardiovasc Pharmacol. 2001 Dec;38(6):940-6
11707698
Cardiovasc Drugs Ther. 2007 Jun;21(3):171-94
17373584
FASEB J. 2001 Aug;15(10):1718-26
11481219
J Biol Chem. 1999 May 14;274(20):13729-32
10318772
Circ Res. 2007 Nov 26;101(11):1084-95
18040025
Circ Res. 2005 Jan 7;96(1):100-9
15576651
Br J Pharmacol. 2009 Jan;156(2):237-49
19154438
Biochem Biophys Res Commun. 1998 Jun 18;247(2):249-54
9642111
J Med Chem. 2003 Oct 9;46(21):4525-32
14521414
Cardiovasc Drugs Ther. 2002 Sep;16(5):417-27
12652111